Ternary Therapeutics is a London-based BioTech startup focused on developing a novel platform that combines physics-informed AI with rapid experimental validation to intentionally engineer molecular glues. Molecular glues are a new class of medicines capable of targeting proteins previously considered undruggable. The company's platform aims to move beyond the historical serendipitous discovery of molecular glues, treating drug discovery as an engineering problem. This approach allows for the predictable design and scaling of these molecules, expanding the range of druggable targets and opening new therapeutic avenues, particularly for inflammatory and neuroinflammatory diseases.